CN115066498A - Pcsk9的拮抗剂 - Google Patents

Pcsk9的拮抗剂 Download PDF

Info

Publication number
CN115066498A
CN115066498A CN202180013447.0A CN202180013447A CN115066498A CN 115066498 A CN115066498 A CN 115066498A CN 202180013447 A CN202180013447 A CN 202180013447A CN 115066498 A CN115066498 A CN 115066498A
Authority
CN
China
Prior art keywords
nucleic acid
sense
molecule
acid molecule
stranded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180013447.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·米切尔
M·卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonot Rna Co ltd
Original Assignee
Argonot Rna Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003756.0A external-priority patent/GB202003756D0/en
Priority claimed from GBGB2010276.0A external-priority patent/GB202010276D0/en
Priority claimed from GBGB2013998.6A external-priority patent/GB202013998D0/en
Priority claimed from GBGB2020553.0A external-priority patent/GB202020553D0/en
Application filed by Argonot Rna Co ltd filed Critical Argonot Rna Co ltd
Publication of CN115066498A publication Critical patent/CN115066498A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21111—Aqualysin 1 (3.4.21.111)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21112—Site-1 protease (3.4.21.112), i.e. subtilisin kexin isozyme-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180013447.0A 2020-03-16 2021-03-15 Pcsk9的拮抗剂 Pending CN115066498A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB2003756.0A GB202003756D0 (en) 2020-03-16 2020-03-16 Antagonist of PCSK9
GB2003756.0 2020-03-16
GBGB2010276.0A GB202010276D0 (en) 2020-07-03 2020-07-03 PCSK9 antagonist
GB2010276.0 2020-07-03
GB2013998.6 2020-09-07
GBGB2013998.6A GB202013998D0 (en) 2020-09-07 2020-09-07 Antagonist of pcsk9
GB2020553.0 2020-12-23
GBGB2020553.0A GB202020553D0 (en) 2020-12-23 2020-12-23 Antagonist of pcsk9
PCT/EP2021/056540 WO2021185765A1 (en) 2020-03-16 2021-03-15 Antagonist of pcsk9

Publications (1)

Publication Number Publication Date
CN115066498A true CN115066498A (zh) 2022-09-16

Family

ID=75111564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180013447.0A Pending CN115066498A (zh) 2020-03-16 2021-03-15 Pcsk9的拮抗剂

Country Status (7)

Country Link
US (1) US20230183694A1 (https=)
EP (1) EP4081642A1 (https=)
JP (1) JP2023519140A (https=)
CN (1) CN115066498A (https=)
CA (1) CA3167849A1 (https=)
GB (1) GB2594788B (https=)
WO (1) WO2021185765A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118147134A (zh) * 2023-11-06 2024-06-07 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041508A2 (en) * 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease
CN117106781B (zh) * 2023-10-16 2024-03-22 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
WO2025252223A1 (zh) * 2024-06-07 2025-12-11 迈威(上海)生物科技股份有限公司 一种抑制PCSK9基因表达的RNAi制剂及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
US20130197055A1 (en) * 2009-01-05 2013-08-01 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
CN109957565A (zh) * 2017-12-26 2019-07-02 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
WO2019126990A1 (zh) * 2017-12-26 2019-07-04 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN118147134A (zh) * 2023-11-06 2024-06-07 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004261002A (ja) * 2003-01-08 2004-09-24 Tsutomu Suzuki ｓｉＲＮＡの製造方法
US8067572B2 (en) 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
CN200950065Y (zh) 2006-05-24 2007-09-19 王锦峰 一种半自动夹板装置
AU2007275365A1 (en) 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
MX2010008394A (es) 2008-01-31 2010-11-12 Alnylam Pharmaceuticals Inc Metodos optimizados para administracion de arndc focalizando el gen pcsk9.
WO2009114475A2 (en) * 2008-03-09 2009-09-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
EP3358014B1 (en) * 2010-04-19 2020-12-23 TAGCyx Biotechnologies Inc. Method for stabilizing functional nucleic acids
WO2012058693A2 (en) 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
ES2770667T3 (es) * 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados que se dirigen a PCSK9
CN118697894A (zh) 2015-08-25 2024-09-27 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
LT3529360T (lt) 2016-10-18 2024-07-25 Novartis Ag Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (pcsk9) baltymo kiekį

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197055A1 (en) * 2009-01-05 2013-08-01 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
CN109957565A (zh) * 2017-12-26 2019-07-02 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
WO2019126990A1 (zh) * 2017-12-26 2019-07-04 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN118147134A (zh) * 2023-11-06 2024-06-07 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
付洁;宋海峰;钱小红;: "siRNA作为基因治疗药物的研究难题", 中国新药杂志, no. 07, 8 April 2007 (2007-04-08), pages 14 - 18 *
李长永;白元;秦永文;: "前蛋白转化酶枯草溶菌素9抑制剂的研究进展", 药学服务与研究, no. 04, 15 August 2013 (2013-08-15), pages 6 - 9 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118147134A (zh) * 2023-11-06 2024-06-07 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN118147134B (zh) * 2023-11-06 2025-02-25 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
TWI908388B (zh) * 2023-11-06 2025-12-11 大陸商杭州天龍藥業有限公司 靶向調控PCSK9基因表達的siRNA及其應用

Also Published As

Publication number Publication date
CA3167849A1 (en) 2021-09-23
GB2594788A (en) 2021-11-10
US20230183694A1 (en) 2023-06-15
JP2023519140A (ja) 2023-05-10
GB202103594D0 (en) 2021-04-28
EP4081642A1 (en) 2022-11-02
GB2594788B (en) 2023-06-07
WO2021185765A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CN115066498A (zh) Pcsk9的拮抗剂
US20250304966A1 (en) Treatment of cardiovascular disease
US20250283076A1 (en) Treatment of cardiovascular disease
CN108472363A (zh) 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
CA3143404C (en) Apolipoprotein b antagonist
US9347085B2 (en) Methods and compositions for reducing amyloid beta levels
JP2023531935A (ja) Ｇタンパク質共役受容体７５（ｇｐｒ７５）阻害剤による肥満の治療
JP2023098926A (ja) Ｔｕｔ４／７発現調節因子を含む癌予防又は治療用薬学的組成物
US20100266579A1 (en) Treatment of inflammatory diseases
CN116139276A (zh) Rnf130及其下调剂在制备自身免疫性疾病药物中的应用
JPWO2021185765A5 (https=)
WO2010115874A1 (en) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
US20140161769A1 (en) Methods for treating inflammatory autoimmune disorders
WO2014018375A1 (en) Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CN101522914A (zh) 丙型肝炎伴发疾病的预防和/或治疗药物的筛选方法
JP7175526B2 (ja) 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
JP2007528707A (ja) 統合失調症の診断および治療のための標的としてのｅｇｒ遺伝子
CN110157705B (zh) 在pdcd1基因表达的剪接水平抑制pd-1信号的反义寡核苷酸及其筛选方法与应用
KR20230055998A (ko) 암 치료 또는 예방용 조성물
JP2009159869A (ja) 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
CN119113120B (zh) p55γ作为主动脉夹层治疗靶点的应用
EP2757152A1 (en) Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent
JP2023141905A (ja) 炎症性腸疾患の予防又は治療剤
JP2013053114A (ja) 肝癌、肝芽腫及び膵癌の治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination